Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (31-40 of 241) with videos related to

Pageof 25
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The clinical pharmacology of antiretrovirals in developmentAlan Winston, Patrick Wg Mallon, Marta Boffito
AIDS (London, England)|January 28, 2026
The evolution of antiretroviral-associated drug-resistance mutations in an individual receiving dolutegravir/lamivudineJesal Gohil, Nicola E Mackie, Alan Winston
AIDS (London, England)|April 14, 2011
Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agentsAlan Winston, Lucy Garvey, Caroline A Sabin
AIDS (London, England)|November 27, 2014
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?Jonathan Underwood, Kevin R Robertson, Alan Winston
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
The rationale and development of new drugs to treat HIV infectionJustin Stebbing, Eleftheria Hatzimichael, Mark Bower, et al.
AIDS (London, England)|September 26, 2024
Anticholinergic and sedative medication use in persons with HIV: defining the evidence for risks on cognitionKarl Goodkin, Alan Winston, Esteban Martinez, et al.
AIDS (London, England)|September 16, 2022
The global burden of cognitive impairment in people with HIVLea D Keng, Alan Winston, Caroline A Sabin
Current Opinion in HIV and AIDS|April 18, 2009
Combining resistance and pharmacology for optimum patient careSaye H Khoo, Alan Winston, David J Back
Sexually Transmitted Infections|April 20, 2021
Predictive value of neurological symptoms in persons with suspected neurosyphilisFareed Shiva, Charlotte-Eve Short, David Goldmeier, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2007
Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment"Lucy Garvey, Emma C Thomson, Janice Main, et al.
Pageof 25

Showing results (31-40 of 241) with videos related to

Sort By:
Pageof 25
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
The clinical pharmacology of antiretrovirals in developmentAlan Winston, Patrick Wg Mallon, Marta Boffito
AIDS (London, England)|January 28, 2026
The evolution of antiretroviral-associated drug-resistance mutations in an individual receiving dolutegravir/lamivudineJesal Gohil, Nicola E Mackie, Alan Winston
AIDS (London, England)|April 14, 2011
Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agentsAlan Winston, Lucy Garvey, Caroline A Sabin
AIDS (London, England)|November 27, 2014
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?Jonathan Underwood, Kevin R Robertson, Alan Winston
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
The rationale and development of new drugs to treat HIV infectionJustin Stebbing, Eleftheria Hatzimichael, Mark Bower, et al.
AIDS (London, England)|September 26, 2024
Anticholinergic and sedative medication use in persons with HIV: defining the evidence for risks on cognitionKarl Goodkin, Alan Winston, Esteban Martinez, et al.
AIDS (London, England)|September 16, 2022
The global burden of cognitive impairment in people with HIVLea D Keng, Alan Winston, Caroline A Sabin
Current Opinion in HIV and AIDS|April 18, 2009
Combining resistance and pharmacology for optimum patient careSaye H Khoo, Alan Winston, David J Back
Sexually Transmitted Infections|April 20, 2021
Predictive value of neurological symptoms in persons with suspected neurosyphilisFareed Shiva, Charlotte-Eve Short, David Goldmeier, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2007
Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment"Lucy Garvey, Emma C Thomson, Janice Main, et al.
Pageof 25